Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | 100.00% | -- | -70.00% | -70.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | 100.00% | -- | -70.00% | -70.00% |
| Cost of Revenue | 27.86% | 20.79% | 46.29% | 86.30% | 124.87% |
| Gross Profit | -41.92% | -17.84% | -32.70% | -302.05% | -687.08% |
| SG&A Expenses | 55.30% | 79.24% | 117.26% | 115.06% | 103.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.27% | 31.08% | 58.37% | 91.76% | 120.27% |
| Operating Income | -44.79% | -28.98% | -47.09% | -235.08% | -387.22% |
| Income Before Tax | -161.50% | -141.33% | -47.40% | -224.60% | -257.02% |
| Income Tax Expenses | -43.75% | -118.41% | -18.94% | -18.94% | -25.58% |
| Earnings from Continuing Operations | -161.21% | -140.62% | -47.24% | -223.26% | -255.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -161.21% | -140.62% | -47.24% | -223.26% | -255.16% |
| EBIT | -44.79% | -28.98% | -47.09% | -235.08% | -387.22% |
| EBITDA | -44.87% | -29.06% | -47.18% | -235.63% | -388.48% |
| EPS Basic | 72.97% | 83.86% | 92.82% | 85.05% | -5.88% |
| Normalized Basic EPS | 83.40% | 90.60% | 92.98% | 75.92% | -37.76% |
| EPS Diluted | 72.97% | 83.86% | 92.82% | 85.17% | -4.24% |
| Normalized Diluted EPS | 83.40% | 90.60% | 92.98% | 78.64% | -15.43% |
| Average Basic Shares Outstanding | 107.15% | 239.00% | 1,257.20% | 2,049.66% | 1,408.09% |
| Average Diluted Shares Outstanding | 107.15% | 239.00% | 1,257.20% | 1,931.55% | 1,324.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |